41 results on '"McAleese, J."'
Search Results
2. Neutrophil lymphocyte ratio as a prognostic marker in patients treated with curative intent radiotherapy for non-small cell lung cancer
3. Investigating the cause of early death after radical lung radiotherapy
4. Oligometastases in extensive disease-small cell lung cancer
5. Oligometastatic relapse after radical radiotherapy for NSCLC
6. Radical radiotherapy alone versus chemoradiotherapy for the treatment of stage III (N2) non-small cell lung cancer
7. Survival following radical radiotherapy for satellite or synchronous ipsilateral nodules
8. Rate of marginal relapse following curative intent radiotherapy in a modern cohort
9. Curative radiotherapy for non-small cell lung cancer in the UK: international benchmarking
10. 129: Survival for patients following radical radiotherapy in the Northern Ireland cancer network in comparison to a large European cohort
11. 134: Marked variability in the access to curative radiotherapy for NSCLC in the UK
12. 135: Re-plan rates for radical radiotherapy in lung cancer
13. 140 Outcomes of salvage radiotherapy in the treatment of NSCLC with loco-regional relapse
14. 151 The incidence of thoracic re-irradiation at 3 UK cancer centres following curative intent radiotherapy for non-small cell lung cancer
15. 160: Review of the national lung cancer audit of SCLC chemotherapy rates in Northern Ireland
16. 151: A UK survey of the practice of re-irradiation of locally relapsed lung cancers after previous thoracic radiotherapy
17. 162: Review of SCLC timelines to assessment and treatment in Northern Ireland
18. 160 The impact of peer review on the radiotherapy treatment planning process in the treatment of lung cancer
19. 210 The first UK audit of curative-intent radiotherapy for non-small cell lung cancer; the need to assess quality and improve outcomes
20. 153 Comparison of PTV geometrics and toxicity between 4DCT and 3DCT for radical treatment of lung cancer: Northern Ireland experience
21. 146 Offering quantitative prognosis to lung cancer patients
22. 26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
23. 156 An audit of the quality of curative intent NSCLC radiotherapy
24. 176 Concurrent chemoradiation for lung cancer in routine practice
25. 78 ‘Garbage in, garbage out’ – assessing the quality of new patient histories by thoracic oncologists
26. 163 Efficacy of prophylactic cranial irradiation in small cell lung cancer, subsequent management of brain metastases
27. 141 Improvements in radical radiotherapy outcomes for early NSCLC in Northern Ireland
28. 142 Validation of the MAASTRO clinic cancer prediction tool for overall survival following radical NSCLC radiotherapy
29. 118 Syndrome of inappropriate antidiuretic hormone (SIADH) in patients with small cell lung cancer & incidence and response to treatment
30. Should patients with bone metastases in advanced non-small cell lung cancer be treated any differently than other stage IV patients?
31. Comparison of Northern Ireland Cancer Network to LUCADA headline figures (2006)
32. Uptake and delivery of adjuvant chemotherapy in resected non-small cell lung cancer: experience in Northern Ireland Cancer Centre
33. What is the shelf life of PET-CT staging of the mediastinum in non-small cell lung cancer?
34. 18F-FDG PET-CT based target volume definition in non-small cell lung cancer reduces inter-observer variation in already PET-CT staged patients
35. Induction chemotherapy in non-small cell lung cancer: experience at the Northern Ireland Cancer Centre
36. High dose palliative radiotherapy in NSCLC; 27Gy/6# and 39Gy/13# – is there equivalence?
37. Risk of brain metastases in non-small cell lung cancer patients treated with induction chemotherapy
38. Palliative chemotherapy in non-small cell lung cancer; a year's audit of 101 patients
39. 42 Post operative radiotherapy and microscopic disease at the bronchial margin for non-small cell lung cancer (NSCLC); audit of 4 years data from the Northern Ireland Cancer Centre
40. 32 Improving outcomes for radical radiotherapy in T1–2N0–1 medically inoperable non-small cell lung cancer (NSCLC); Northern Ireland experience 2001–2004
41. Re-challenge gemcitabine carboplatin in the “second-line” setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.